Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $205.81, a 24.74% upside from current levels. In a report released on November 14, Wolfe Research also ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

we should understand the company’s fundamentals and its strengths and weaknesses to better analyze how to play the stock after the recent price dip. ABBV’s Successful New Drugs — Skyrizi and ...